Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Observational Health Data Sciences and Informatics (OHDSI) international community will host a COVID-19 virtual study-a-thon this week (March 26-29) to inform healthcare decision-making in response to the current global pandemic.

It is being held in lieu of the cancelled OHDSI European Symposium, which would have taken place in Oxford. Lead organiser Daniel Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS said: "Our organising committee was hit quite hard when we realised it would be necessary to cancel our long-awaited OHDSI European Symposium, but we quickly realised that our community could come together and make a difference in this global pandemic."

"We are using the time for a COVID-19 virtual study-a-thon that will catalyze a long journey of shared research ahead. Based on the early enthusiasm of our many registrants, I'm optimistic that we can make important progress on the journey and make a meaningful contribution to this international effort."

More than 290 people from 29 different countries have registered for the four-day online event. Alongside the Oxford team are researchers from Erasmus Medical Center, Columbia University, UCLA, Ajou University, Janssen Research and Development, and IQVIA with active participation across government, industry, and academia.

Read more on the Nuffield Department of Orthoapaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) website

Similar stories

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.